Ouaknine Krief, Julia de Tauriers, Pierre Helly Dumenil, Coraline Neveux, Nathalie Dumoulin, Jennifer Giraud, Violaine Labrune, Sylvie Tisserand, Julie Julie, Catherine Emile, Jean-François Chinet, Thierry Leprieur, Etienne Giroux Additional file 1: of Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab Figure S1. Repartition of the antibiotic classes in early use of antibiotics (EUA) group for each prescription (n = 51). Figure S2. Therapeutic indications of EUA (n = 51). Figure S3. Main bacteria phylum in blood at baseline in the overall population (n = 35). Figure S4. LEFSE diagram of blood microbiome at M0 according to tumor response. Figure S5. LEFSE diagram of blood microbiome at M0 according to clinical benefit Figure S6. LEFSE diagram of blood microbiome at M2 according to early use of antibiotic (EUA). (DOCX 2147 kb) Non-small cell lung cancer;Antibiotic;Plasma;Blood;Microbiome;Citrulline;Nivolumab;Biomarker 2019-07-10
    https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_of_Role_of_antibiotic_use_plasma_citrulline_and_blood_microbiome_in_advanced_non-small_cell_lung_cancer_patients_treated_with_nivolumab/8857847
10.6084/m9.figshare.8857847.v1